From these findings then it is hypothesised that the misbalance in the activities of HATs/HDACs could be rectified with the use of HDAC inhibitors (HDACIs) to reduce the extent of cell death in the nigrostriatal pathways in PD [10,13,19,22,29]. The gene discussed is HDAC9; the disease is Parkinson disease.